CVE-2018-14786
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH...
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH, Alaris CC, and Alaris TIVA) versions 2.3.6 and prior are affected by an improper authentication vulnerability where the software does not perform authentication for functionality that requires a provable user identity, where it may allow a remote attacker to gain unauthorized access to various Alaris Syringe pumps and impact the intended operation of the pump when it is connected to a terminal server via the serial port.
Attack profile
How easy it is to exploit
- Attack vector
- Network
- Complexity
- Low
- Privileges needed
- None
- User interaction
- None
What an attacker can affect
- Confidentiality
- Low
- Integrity
- High
- Availability
- High
Exploit likelihood
What each source reports
NVD Score used
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH, Alaris CC, and Alaris TIVA) versions 2.3.6 and prior are affected by an improper authentication vulnerability where the software does not perform authentication for functionality that requires a provable user identity, where it may allow a remote attacker to gain unauthorized access to various Alaris Syringe pumps and impact the intended operation of the pump when it is connected to a terminal server via the serial port.
- Record
CVE-2018-14786- CVSS 3.0
- 9.4 Critical
CVSS:3.0/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H - CVSS 2.0
- 7.5 High
AV:N/AC:L/Au:N/C:P/I:P/A:P - Weakness
- CWE-287
- Updated
- 2026-11-02
CVE List No score
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH, Alaris CC, and Alaris TIVA) versions 2.3.6 and prior are affected by an improper authentication vulnerability where the software does not perform authentication for functionality that requires a provable user identity, where it may allow a remote attacker to gain unauthorized access to various Alaris Syringe pumps and impact the intended operation of the pump when it is connected to a terminal server via the serial port.
- Record
CVE-2018-14786- Weakness
- CWE-287
- Updated
- 2026-11-02
EUVDEUVD-2018-6670 No score
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH, Alaris CC, and Alaris TIVA) versions 2.3.6 and prior are affected by an improper authentication vulnerability where the software does not perform authentication for functionality that requires a provable user identity, where it may allow a remote attacker to gain unauthorized access to various Alaris Syringe pumps and impact the intended operation of the pump when it is connected to a terminal server via the serial port.
- Record
EUVD-2018-6670- Updated
- 2026-11-03
GitHub AdvisoriesGHSA-vf2m-j6h8-v6c5
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH...
Becton, Dickinson and Company (BD) Alaris Plus medical syringe pumps (models Alaris GS, Alaris GH, Alaris CC, and Alaris TIVA) versions 2.3.6 and prior are affected by an improper authentication vulnerability where the software does not perform authentication for functionality that requires a provable user identity, where it may allow a remote attacker to gain unauthorized access to various Alaris Syringe pumps and impact the intended operation of the pump when it is connected to a terminal server via the serial port.
- Record
GHSA-vf2m-j6h8-v6c5- CVSS 3.0
- 9.4 Critical
CVSS:3.0/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:H/A:H - Weakness
- CWE-287
- Updated
- 2026-11-02
Affected products
History
| Recorded | Changed | Sources |
|---|---|---|
| aliases | EUVD | |
| first indexed | CVE List, GitHub Advisories, NVD |
Dates are when Every CVE recorded each change. Upstream dates may differ.
In short
CVE-2018-14786 is a critical vulnerability (CVSS 9.4) in Becton, Dickinson And Company Alaris Gs, Alaris Gh, Alaris Cc, And Alaris Tiva, published August 23, 2018. No source lists public exploit code. EPSS puts the chance of exploitation in the next 30 days at 2.94%, the 87th percentile. No source names a fixed version.
References
securityfocus.com/bid/105147
bd.com/en-us/support/product-security-and-privacy/product-security-bulletin-for-various-alaris-plus-syringe-pumps-sold-and-in-use-outside-the-united-states
ics-cert.us-cert.gov/advisories/ICSMA-18-235-01
nvd.nist.gov/vuln/detail/CVE-2018-14786
github.com/advisories/GHSA-vf2m-j6h8-v6c5